Global Anterior Horn Cell Disease Market – Industry Trends and Forecast to 2030

Global Anterior Horn Cell Disease Market, By Drug Type (Riluzole, Edaravone (Radicava), Glutamate Receptor Antagonist and  Others), Disease Type (Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, Multifocal Motor Neuropathy and Others), Diagnosis (EMG/NCS, Serum and Urine Electrophoresis, Serum Immunoelectrophoresis, Quantitative Immunoglobulins, Anti-GM1 Antibody Levels), Treatment Type (Neurotherapy, Chemotherapy, Cell Therapy and Others), Route of Administration (Oral, Injection, Transdermal), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2030.

Anterior Horn Cell Disease Market Analysis and Size

The anterior horn cell disease market is expected to witness significant growth during the forecast period. Disorders of the anterior horn cell (AHC) can either be acquired or inherited. The increase in the geriatric population are vulnerable to disease globally, acts as one of the major factors driving the growth of the market. The increase in the R&D activities by the pharmaceutical and biotechnology companies to improve the treatment and adoption of lifestyle alterations such as unhealthy eating habits, increased stress and unhealthy eating habits expand the market growth.

Data Bridge Market Research analyses a growth rate in the anterior horn cell disease market in the forecast period 2023-2030. The expected CAGR of anterior horn cell disease market is tend to be around 4.50% in the mentioned forecast period. The market was valued at USD 0.70 billion in 2022, and it would grow upto USD 1 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Anterior Horn Cell Disease Market Scope and Segmentation

Market Definition

Anterior horn disease is a medical disorder affecting the spinal cord's anterior horn containing the motor neurons that are highly responsible for body muscles. Spinal muscular atrophy, progressive muscular atrophy, poliomyelitis, and amyotrophic lateral sclerosis are some of the major diseases that are often sub-divided under anterior horn. This disease involves selective involvement of muscles.

Anterior Horn Cell Disease Market Dynamics

Drivers

• Increase in Ageing Population

Numerous studies have shown that elderly population is more susceptible to suffer from this disease. According to the Aging World reports from 2015, there were about 562 million people 65 and older globally, which increased the disease's incidence and expanded the market's growth.

• Increase In The Number Of R&D Activities       

The market's growth is pushed by the increase in the number of R&D activities. This will provide much beneficial opportunities for the global anterior horn cell disease market. Government is funding many of the research projects and launches to encourage researchers and pharmaceutical companies for the development of novel medicines

Opportunities

• Wide Availability Of Diagnostic Methods

The increasing availability of several diagnostic methods are increasing the market growth. Diagnostic testing for this condition includes serum immunoelectrophoresis, EMG/NCS, quantitative immunoglobulins, serum and urine electrophoresis, and anti-GM1 antibody levels.  Thus, all these unique and different methods create opportunities for the market growth.

Restraints/Challenges

• Lack Of Skilled Professionals

The lack of healthcare professionals who cannot identify the disease and state the underlying treatments could decrease the market's growth during a forecast period 2023-2030.

• Unavailability of Appropriate Treatments

To treat rare conditions, at times all treatments are not available, mainly in the under-developed countries. The severe patients’ needs to be treated with the advanced specific techniques but these are not available in the hospitals and clinics. Thus, it hampers the market growth.

This anterior horn cell disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anterior horn cell disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Anterior Horn Cell Disease Market Scope

The anterior horn cell disease market is segmented on the basis of drug type, disease type, diagnosis, treatment type, route of administration, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Type

• Riluzole
• Edaravone
• Glutamate Receptor Antagonist
• Others

Disease Type

• Amyotrophic Lateral Sclerosis
• Spinal Muscular Atrophy
• Multifocal Motor Neuropathy
• Others

Diagnosis

• EMG/NCS
• Serum and Urine Electrophoresis
• Serum Immunoelectrophoresis
• Quantitative Immunoglobulins
• Anti-GM1 Antibody Levels

Treatment Type

• Neurotherapy
• Chemotherapy
• Cell Therapy
• Others

Route of Administration

• Oral
• Injection
• Transdermal

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Anterior Horn Cell Disease Market Regional Analysis/Insights

The anterior horn cell disease market is analysed and market size insights and trends are provided by drug type, disease type, diagnosis, treatment type, route of administration, end-user, distribution channel as referenced above.

The major countries covered in the anterior horn cell disease market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market due to the prevalence of motor neuron diseases and well-developed healthcare infrastructure within the region.  

Asia-Pacific is considered to have the most lucrative period because of the developing healthcare facilities, large number of manufacturers and government initiatives.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Anterior Horn Cell Disease Market Share Analysis

The anterior horn cell disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to anterior horn cell disease market.

Key players operating in the anterior horn cell disease market include:

• Sanofi (France)
• Novartis AG (Switzerland)
• Mitsubishi Chemical Group Corporation.(Japan)
• BrainStorm Cell Limited (U.S.)
• Ionis Pharmaceuticals (U.S.)
• Genervon Biopharmaceuticals, LLC (U.S.)
• Bausch Health Companies Inc. (Canada)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Treeway B.V. (Netherlands)
• CYTOKINETICS (U.S.)
• AB Science (France)
• ADVANZ PHARMA (U.K.)
• Biogen (U.S.)
• Orphazyme (U.S.)
• KRIGLE PHARMA, INC (Japan)
• Aquestive Therapeutics, Inc (U.S.)
• Apotex Inc (Canada)